485 related articles for article (PubMed ID: 18612536)
41. Thrombin activatable fibrinolysis inhibitor: at the nexus of fibrinolysis and inflammation.
Colucci M; Semeraro N
Thromb Res; 2012 Mar; 129(3):314-9. PubMed ID: 22113149
[TBL] [Abstract][Full Text] [Related]
42. Overweight, obesity, and the risk of recurrent venous thromboembolism.
Eichinger S; Hron G; Bialonczyk C; Hirschl M; Minar E; Wagner O; Heinze G; Kyrle PA
Arch Intern Med; 2008 Aug; 168(15):1678-83. PubMed ID: 18695082
[TBL] [Abstract][Full Text] [Related]
43. Thrombosis risk in systemic lupus erythematosus: the role of thrombophilic risk factors.
Sallai KK; Nagy E; Bodó I; Mohl A; Gergely P
Scand J Rheumatol; 2007; 36(3):198-205. PubMed ID: 17657674
[TBL] [Abstract][Full Text] [Related]
44. Thrombosis: new culprits in an old disorder.
Federman DG; Moriarty JP; Kravetz JD; Kirsner RS
Panminerva Med; 2002 Jun; 44(2):107-13. PubMed ID: 12032428
[TBL] [Abstract][Full Text] [Related]
45. Thrombin activatable fibrinolysis inhibitor (TAFI) is not associated with fetal loss, a retrospective study.
Folkeringa N; Korteweg FJ; Veeger NJ; Middeldorp S; Hamulyak K; Prins MH; Erwich JJ; Büller HR; van der Meer J
Thromb Res; 2009; 123(3):511-4. PubMed ID: 18455758
[No Abstract] [Full Text] [Related]
46. Hereditary thrombophilic risk factors and venous thromboembolism in Istanbul, Turkey: the role in different clinical manifestations of venous thromboembolism.
Okumus G; Kiyan E; Arseven O; Tabak L; Diz-Kucukkaya R; Unlucerci Y; Abaci N; Unaltuna NE; Issever H
Clin Appl Thromb Hemost; 2008 Apr; 14(2):168-73. PubMed ID: 17895505
[TBL] [Abstract][Full Text] [Related]
47. Circulating P-selectin and the risk of recurrent venous thromboembolism.
Kyrle PA; Hron G; Eichinger S; Wagner O
Thromb Haemost; 2007 Jun; 97(6):880-3. PubMed ID: 17549288
[TBL] [Abstract][Full Text] [Related]
48. Plasma levels of thrombin activatable fibrinolysis inhibitor in normal and preeclamptic pregnant women.
Alacacioğlu I; Ozcan MA; Alacacioğlu A; Polat M; Yüksel F; Demirkan F; Pişkin O; Ozgenç Y; Ozsan HG; Undar B
Thromb Res; 2004; 114(3):155-9. PubMed ID: 15342211
[TBL] [Abstract][Full Text] [Related]
49. The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.
Ozeren M; Karahan SC; Ozgur M; Eminagaoglu S; Unsal M; Baytan S; Bozkaya H
Acta Obstet Gynecol Scand; 2005 Oct; 84(10):987-91. PubMed ID: 16167916
[TBL] [Abstract][Full Text] [Related]
50. High factor VIII levels independently predict venous thromboembolism in cancer patients: the cancer and thrombosis study.
Vormittag R; Simanek R; Ay C; Dunkler D; Quehenberger P; Marosi C; Zielinski C; Pabinger I
Arterioscler Thromb Vasc Biol; 2009 Dec; 29(12):2176-81. PubMed ID: 19778945
[TBL] [Abstract][Full Text] [Related]
51. [Antiphospholipid syndrome and venous thromboembolism: the role of congenital thrombophilia].
Poli D; Gensini GF
Ann Ital Med Int; 2005; 20(4):218-23. PubMed ID: 16610253
[TBL] [Abstract][Full Text] [Related]
52. Risk of deep vein thrombosis: interaction between oral contraceptives and high factor VIII levels.
Legnani C; Cini M; Cosmi B; Poggi M; Boggian O; Palareti G
Haematologica; 2004 Nov; 89(11):1347-51. PubMed ID: 15531457
[TBL] [Abstract][Full Text] [Related]
53. [Thrombin activatable fibrinolysis inhibitor (TAFI) in allergic asthma patients].
Kemona-Chetnik I; Kowal K; Kucharewicz I; Pampuch A; Bodzenta-Lukaszyk A
Przegl Lek; 2006; 63(12):1281-5. PubMed ID: 17642140
[TBL] [Abstract][Full Text] [Related]
54. Decrements in the thrombin activatable fibrinolysis inhibitor (TAFI) levels in association with orlistat treatment in obesity.
Guven GS; Kiliçaslan A; Oz SG; Haznedaroglu IC; Kirazli S; Aslan D; Sözen T
Clin Appl Thromb Hemost; 2006 Jul; 12(3):364-8. PubMed ID: 16959692
[TBL] [Abstract][Full Text] [Related]
55. Inherited thrombophilia and venous thromboembolism.
Simioni P; Tormene D; Spiezia L; Tognin G; Rossetto V; Radu C; Prandoni P
Semin Thromb Hemost; 2006 Oct; 32(7):700-8. PubMed ID: 17024597
[TBL] [Abstract][Full Text] [Related]
56. Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis.
Ricart JM; Ramón LA; Vayá A; España F; Santaolaria ML; Todolí J; Castelló R; Fontcuberta J; Estellés A
Br J Haematol; 2008 May; 141(5):716-9. PubMed ID: 18341631
[TBL] [Abstract][Full Text] [Related]
57. Is exogenous tissue plasminogen activator necessary for antithrombotic efficacy of an inhibitor of thrombin activatable fibrinolysis inhibitor (TAFI) in rats?
Bird E; Tamura J; Bostwick JS; Steinbacher TE; Stewart A; Liu Y; Baumann J; Feyen J; Tamasi J; Schumacher WA
Thromb Res; 2007; 120(4):549-58. PubMed ID: 17229457
[TBL] [Abstract][Full Text] [Related]
58. Risk of venous thromboembolism after air travel: interaction with thrombophilia and oral contraceptives.
Martinelli I; Taioli E; Battaglioli T; Podda GM; Passamonti SM; Pedotti P; Mannucci PM
Arch Intern Med; 2003 Dec 8-22; 163(22):2771-4. PubMed ID: 14662632
[TBL] [Abstract][Full Text] [Related]
59. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
Koutroubakis IE; Sfiridaki A; Tsiolakidou G; Coucoutsi C; Theodoropoulou A; Kouroumalis EA
Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):912-6. PubMed ID: 18794606
[TBL] [Abstract][Full Text] [Related]
60. Intrinsic clotting factors in dependency of age, sex, body mass index, and oral contraceptives: definition and risk of elevated clotting factor levels.
Luxembourg B; Schmitt J; Humpich M; Glowatzki M; Seifried E; Lindhoff-Last E
Blood Coagul Fibrinolysis; 2009 Oct; 20(7):524-34. PubMed ID: 19620844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
